Why did MLOCT.PA stock fall sharply in pre-market trading?

The fall to **€0.125** on 05 Mar 2026 reflects a liquidity-driven sell-off. Volume was **34,661**, far above the average **4,058**, and there were no new earnings announcements. Thin trading can amplify moves when holders reduce positions.

What are the key valuation risks for MLOCT.PA stock?

Valuation risks include negative book value per share, P/S **303.79**, EPS **-0.04**, and a current ratio of **0.31**. These metrics point to weak balance-sheet resilience and limited short-term liquidity.

What is Meyka AI’s forecast and price target for MLOCT.PA stock?

Meyka AI's forecast model projects a yearly price of **€0.22585**, implying **80.68%** upside from **€0.125**. The model also flags a nearer-term target of **€0.20**. Forecasts are projections, not guarantees.

How should traders manage risk around MLOCT.PA stock today?

Use small position sizes, limit orders, and set stop-losses. Wait for confirmation of a volume-backed rebound above **€0.17** or an RSI recovery above **40** before increasing exposure.

EU Stocks

Pre-Market: Octopus Biosafety (MLOCT.PA) -21.88% on EURONEXT: liquidity concern

ByDanny Kontos March 5, 2026March 5, 2026

MLOCT.PA stock opened the pre-market session on 05 Mar 2026 at €0.125, down 21.88% from Thursday’s close. The drop comes on higher-than-usual volume at 34,661 shares versus an average of 4,058, signaling a sharp sell-off in a thinly traded name on EURONEXT. No new earnings release is scheduled, and market reaction points to liquidity and valuation concerns rather than fresh company disclosure. We review key metrics, technical signals, and Meyka AI’s forecast to explain why Octopus Biosafety (MLOCT.PA) sits among today’s top losers